Early identification and optimal management of carbapenem-resistant Gram-negative infection

被引:10
作者
Bedos, J. P. [1 ]
Daikos, G. [2 ]
Dodgson, A. R. [3 ,4 ]
Pan, A. [5 ]
Petrosillo, N. [6 ,7 ]
Seifert, H. [8 ]
Vila, J. [9 ]
Ferrer, R. [10 ]
Wilson, P. [11 ]
机构
[1] Ctr Hosp Versailles, Intens Care Unit, Le Chesnay, France
[2] Natl & Kapodistrian Univ Athens, Laikon Hosp, Med Sch, Dept Propaedeut Med 1, Athens, Greece
[3] Cent Manchester Univ Hosp NHS Fdn Trust, Dept Microbiol, Manchester, Lancs, England
[4] Manchester Royal Infirm, Publ Hlth Lab, Publ Hlth England, Manchester, Lancs, England
[5] ASST Cremona, Div Infect Dis, Cremona, Italy
[6] IRCCS, Natl Inst Infect Dis Lazzaro Spallanzani, Clin & Res Infect Dis Dept, Rome, Italy
[7] IRCCS, Natl Inst Infect Dis Lazzaro Spallanzani, Infect Dis Unit, Rome, Italy
[8] Univ Cologne, Inst Med Microbiol Immunol & Hyg, Cologne, Germany
[9] Univ Barcelona, Hosp Clin, Dept Clin Microbiol, ISGlobal, Barcelona, Spain
[10] Vall dHebron Univ Hosp, Intens Care Dept, Barcelona, Spain
[11] Univ Coll London Hosp, Dept Microbiol & Virol, London, England
关键词
Carbapenem resistance; Survey; Screening; Diagnosis; Infection control; Antibiotic stewardship;
D O I
10.1016/j.jhin.2020.12.001
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Carbapenem resistance in Gram-negative bacteria is associated with severe infections in the hospital setting. No uniform screening policy or agreed set of criteria exists within the EU to inform treatment decisions for infections caused by carbapenemAim: To develop a range of consensus statements to survey experts in carbapenem resistance, to identify potential similarities and differences across the EU and across specialties. Methods: The survey contained 43 statements, covering six key topics relating to carbapenem-resistant organisms: microbiological screening; diagnosis; infection control implementation; antibiotic stewardship; use of resources; and influencing policy. Findings: In total, 136 survey responses were received (66% infectious disease specialists, 18% microbiologists, 11% intensive care specialists, 4% other/unknown) from France, Germany, Greece, Italy, Spain, and the UK. High, or very high, levels of agreement were seen for all 43 consensus statements, indicating good alignment concerning early identification and optimal management of infection due to carbapenem-resistant organisms. Conclusion: We offer the following recommendations: (1) screening is required when a patient may have been exposed to the healthcare system in countries/hospitals where carbapenem-resistant organisms are endemic; (2) rapid diagnostic tools should be available in every institution; (3) all institutions should have a specific policy for the control of carbapenem-resistant organisms, which is routinely audited; (4) clear strategies are required to define both appropriate and inappropriate use of carbapenems; (5) priority funding should be allocated to the management of infections due to carbapenem-resistant organisms; and (6) international co-operation is required to reduce country-to-country transmission of carbapenem-resistant organisms. (c) 2020 The Authors. Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:158 / 167
页数:10
相关论文
共 20 条
[1]   An Emerging Clone, Klebsiella pneumoniae Carbapenemase 2-Producing K. pneumoniae Sequence Type 16, Associated With High Mortality Rates in a CC258-Endemic Setting [J].
Andrey, Diego O. ;
Dantas, Priscila Pereira ;
Martins, Willames B. S. ;
De Carvalho, Fabiola Marques ;
Almeida, Luiz Gonzaga Paula ;
Sands, Kirsty ;
Portal, Edward ;
Sauser, Julien ;
Cayo, Rodrigo ;
Nicolas, Marisa F. ;
Vasconcelos, Ana Tereza R. ;
Medeiros, Eduardo A. ;
Walsh, Timothy R. ;
Gales, Ana C. .
CLINICAL INFECTIOUS DISEASES, 2020, 71 (07) :E141-E150
[2]   Risk factors and influence of carbapenem exposure on the development of carbapenem resistant Pseudomonas aeruginosa bloodstream infections and infections at sterile sites [J].
Barron, Michelle A. ;
Richardson, Kris ;
Jeffres, Meghan ;
McCollister, Bruce .
SPRINGERPLUS, 2016, 5
[3]   Treatment of Infections Due to MDR Gram-Negative Bacteria [J].
Bassetti, Matteo ;
Peghin, Maddalena ;
Vena, Antonio ;
Giacobbe, Daniele Roberto .
FRONTIERS IN MEDICINE, 2019, 6
[4]   Ready for a world without antibiotics? The Pensieres Antibiotic Resistance Call to Action [J].
Carlet, Jean ;
Jarlier, Vincent ;
Harbarth, Stephan ;
Voss, Andreas ;
Goossens, Herman ;
Pittet, Didier .
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 2012, 1
[5]   AN EXPERIMENTAL APPLICATION OF THE DELPHI METHOD TO THE USE OF EXPERTS [J].
DALKEY, N ;
HELMER, O .
MANAGEMENT SCIENCE, 1963, 9 (03) :458-467
[7]  
European Centre for Disease Prevention and Control, 2018, DAT ECDC SURV ATL AN
[8]  
European Centre for Disease Prevention and Control and European Medicines Agency, 2009, EMEA5761762009 EUR C
[9]  
Kost K, 2017, PRACT LAB MED, V8, P18, DOI 10.1016/j.plabm.2017.03.002
[10]   Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance [J].
Magiorakos, A. -P. ;
Srinivasan, A. ;
Carey, R. B. ;
Carmeli, Y. ;
Falagas, M. E. ;
Giske, C. G. ;
Harbarth, S. ;
Hindler, J. F. ;
Kahlmeter, G. ;
Olsson-Liljequist, B. ;
Paterson, D. L. ;
Rice, L. B. ;
Stelling, J. ;
Struelens, M. J. ;
Vatopoulos, A. ;
Weber, J. T. ;
Monnet, D. L. .
CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (03) :268-281